Accéder au contenu
Merck
  • Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation.

Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation.

Proceedings of the National Academy of Sciences of the United States of America (2013-03-27)
Stephen R Clark, Christopher P Thomas, Victoria J Hammond, Maceler Aldrovandi, Gavin W Wilkinson, Keith W Hart, Robert C Murphy, Peter W Collins, Valerie B O'Donnell
RÉSUMÉ

Aminophospholipid (APL) trafficking across the plasma membrane is a key event in cell activation, apoptosis, and aging and is required for clearance of dying cells and coagulation. Currently the phospholipid molecular species externalized are unknown. Using a lipidomic method, we show that thrombin, collagen, or ionophore-activated human platelets externalize two phosphatidylserines (PSs) and five phosphatidylethanolamines (PEs). Four percent of the total cellular PE/PS pool (∼300 ng/2 × 10(8) cells, thrombin), is externalized via calcium mobilization and protease-activated receptors-1 and -4, and 48% is contained in microparticles. Apoptosis and energy depletion (aging) externalized the same APLs in a calcium-dependent manner, and all stimuli externalized oxidized phospholipids, termed hydroxyeicosatetraenoic acid-PEs. Transmembrane protein-16F (TMEM-16F), the protein mutated in Scott syndrome, was required for PE/PS externalization during thrombin activation and energy depletion, but not apoptosis. Platelet-specific APLs optimally supported tissue factor-dependent coagulation in human plasma, vs. APL with longer or shorter fatty acyl chains. This finding demonstrates fatty acids as molecular determinants of APL that regulate hemostasis. Thus, the molecular species of externalized APL during platelet activation, apoptosis, and energy depletion were characterized, and their ability to support coagulation revealed. The findings have therapeutic implications for bleeding disorders and transfusion therapy. The assay could be applied to other cell events characterized by APL externalization, including cell division and vesiculation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Thrombine from human plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280, 18.3)
Sigma-Aldrich
Thrombine from bovine plasma, lyophilized powder, 40-300 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombine from bovine plasma, lyophilized powder, 600-2,000 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombine from human plasma, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)
Sigma-Aldrich
Thrombine from bovine plasma, ≥60 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombine from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
Sigma-Aldrich
Thrombine from human plasma, lyophilized powder, Suitable for routine use in the thrombin time test
Sigma-Aldrich
Thrombin human, BioUltra, recombinant, expressed in HEK 293 cells, aqueous solution, ≥95% (SDS-PAGE)
Sigma-Aldrich
Thrombine from human plasma, lyophilized powder, 1500-3500 NIH units/mg protein (E1%/280, 18.3), suitable for cell culture
Sigma-Aldrich
Thrombine from human plasma, lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)
Sigma-Aldrich
Thrombine from human plasma, 400-1000 NIH units/mg protein